Try our beta test site
503 studies found for:    cutaneous [CONDITION] AND "lymphoma "[CONDITION]
Show Display Options
Rank Status Study
1 Unknown  Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Lenalidomide
2 Completed
Has Results
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Interventions: Drug: placebo for SHAPE (SHP-141);   Drug: SHAPE (SHP-141) 0.1% BID;   Drug: SHAPE (SHP-141) 0.5% BID;   Drug: SHAPE (SHP-141) 1.0% BID
3 Terminated Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Conditions: Cutaneous Lymphoma;   Cutaneous T-cell Lymphoma
Interventions: Procedure: TSEBT;   Drug: Vorinostat
4 Recruiting Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Micro needle array-Doxorubicin (MNA-D)
5 Recruiting A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma
Intervention: Drug: E7777
6 Active, not recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Condition: Cutaneous T-Cell Lymphoma
Interventions: Biological: KW-0761;   Drug: Vorinostat
7 Active, not recruiting Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma
Condition: Cutaneous T-cell Lymphoma
Intervention: Radiation: HITS
8 Completed Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Panobinostat
9 Completed Long-term Use of Romidepsin in Patients With CTCL
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: Romidepsin
10 Completed Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: ONTAK (denileukin difitox, DAB389IL-2)
11 Completed CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: PF-3512676
12 Withdrawn Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Sirolimus 0.1% Ointment
13 Completed Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
14 Completed A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: APO866
15 Completed Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
16 Completed A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: Quisinostat, 12 mg
17 Completed Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: HuMax-CD4
18 Completed Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: HuMax-CD4
19 Withdrawn Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Curcumin (Turmeric);   Behavioral: Questionnaires;   Other: Photos
20 Completed Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Condition: Refractory Cutaneous T-cell Lymphoma
Intervention: Drug: bexarotene

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.